| 1981 |
|
| |
- Business founded by Joel C. Bradley, Ph.D., MIT, to provide isotopically labeled research compounds and NMR solvents to the new and developing commercial market for stable isotope labeled compounds.
|
| 1983 |
|
| |
- Moved from Cambridge, Massachusetts to larger laboratory space in Woburn, Massachusetts to accommodate the expanding staff and laboratories.
- Provided PCB and PCDF standards in response to transformer fires in Binghamton, NY and San Francisco, CA which emitted PCBs and PCDFs into the atmosphere.
|
| 1985 |
|
| |
- Established international presence with first major Sales Representative in Europe.
- Developed standards for EPA assessment of the contamination at Times Beach, MO which was the “largest civilian exposure to dioxin in the US”
|
| 1986 |
|
| |
- Founded CIL Japan and established offices in Osaka and Tokyo.
|
| 1987 |
|
| |
- Raised expansion capital in an initial public offering on the Securities market in the United Kingdom.
- Construction begins on $3.2 million 13C separation facility in Xenia, Ohio, the largest facility of its kind at the time.
- Supplied standards for epidemiological study of long term affects of dioxins found in Agent Orange.
|
| 1988 |
|
| |
- Acquired the stable isotope division of ICN Biomedicals, a competitor in stable isotope research products.
- Established the first field sales force in the industry in the United States.
|
| 1990 |
|
| |
- Invested in the first super conducting FT/NMR spectrometer to match the quality assurance capabilities of our best customers.
|
| 1992 |
|
| |
- Achieved $10 Million in sales.
- Purchased a second super conducting FT/NMR spectrometer.
- First produced 13C PAH standards
|
| 1993 |
|
| |
- Acquired the assets of MSD Isotopes from Merck Frost of Canada, a major competitor and the oldest stable isotope company in the industry.
- Awarded $100,000 in 13C products in the first CIL Research Grant Program to promote novel applications of 13C by the research community.
|
| 1994 |
|
| |
- Built state-of-the-art laboratories at our new site in Andover, Massachusetts to bring all laboratory operations under one roof and to provide space for expansion.
- Implemented GMP programs.
- Established biochemical synthesis facility in Canada
- Introduced 1st generation of cell growth media
- 18O first produced
|
| 1995 |
|
| |
- Awarded over $100,000 in 13C & D compounds in a second CIL Research Grant Program.
- 13C Urea manufactured to cGMP
- CIL catalog introduced as evidence in the OJ Simpson
“Trial of the Century”
|
| 1996 |
|
| |
- Significant expansion of production capacity of 13C separation facility in Ohio to meet the growing demand, again the largest facility of its kind at the time.
|
| 1997 |
|
| |
- Development of BioExpress, 2nd generation cell growth media
|
| 1998 |
|
| |
- Corporate merger with Otsuka Pharmaceuticals to facilitate a joint development of certain medical diagnostic products. CIL continues operations with the same executives and key managers and with an independent Board of Directors.
- Former Senator John Glenn, infused with CIL amino acids
for tracer studies during shuttle mission
- Developed 13C PBDE standards
|
| 1999 |
|
| |
- Construction begins on $6 Million 18O separation facility in Xenia, Ohio to meet the rapidly expanding needs of the Positron Emission Tomography (PET) and the metabolism research markets, again the largest in the world.
- Synthesized 13C labeled cyclodiene pestides for CDC/ NHANES exploring human pesticide exposure in families of agricultural workers.
|
| 2001 |
|
| |
- Completed construction on 18O separation facility.
- Established close partnership with Euriso-top S.A
|
| 2000 |
|
| |
- Exceeded $25 million in sales
|
| 2001 |
|
| |
- First expansion of 18O separation facility production completed
- Acquired Euriso-top S.A., largest stable isotope company in Europe
|
| 2002 |
|
| |
- Acquired Tracer Technologies inventory of metabolic substrates
|
| 2003 |
|
| |
- Completed 2nd expansion of 18O separation facility increasing production capacity to 250kg becoming world’s largest producer of 18O
- Collaboration established with P.S.F. (Protein Structure Factory)
- CIL and Cerilliant collaborate on chemical weapon
standards for Homeland Security after 9/11
|
| 2004 |
|
| |
- Exceed $45 million in sales
- Introduced Insect Cell Growth Media
- Collaboration established with Silantes, for RNA/DNA products
- Provided dioxin standards for the forensic analysis on the poisoning of Victor Yushchenko
|
| 2005 |
- Completed 15,000 sq ft expansion of QC, Production, and GMP laboratories
- Established Otsuka Japanese based sales group
- Increased cGMP API manufacturing
|
| 2006 |
|
| |
- Cambridge Isotope Laboratories (Cil) Acquires Nuclear Medicine Chemical Manufacturer Abx Advanced Biochemical Compounds (Abx)
- Introduced Mammalian Cell Growth Media
- Became sponsors of triennial ISMAR prize
- Collaboration established with Cassia, LLC founded by Dr. Jamie Williamson, for RNA/DNA products
- Began distribution of NMR tubes for Norell
|
| 2007 |
|
| |
- Cambridge Isotope Laboratories, Inc. Acquires M-fold Biotech GmbH
|
| 2008 |
|
| |
- Cambridge Isotope Laboratories, Inc. (CIL) Announces Collaborative Venture with Membrane Receptor Technologies, LLC (MRT)
- Cambridge Isotope Laboratories (CIL) and Cell Free Sciences (CFS) Announce Distribution Agreement
- Cambridge Isotope Laboratories (Cil) Acquires Spectra Stable Isotopes (Ssi)
|
| 2010 |
|
| |
- Developed Environmental Standard for the Gulf Oil Crisis
|
| |
|
| |
|
